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Low density lipoprotein (LDL) processing has been investigated in the subcloned human colonic 
carcinoma cell line HT29-18. LDL binding at 4~ was a saturable process in relation to time and LDL 
concentration. The Kd for LDL binding was 11 #g/ml. ApoE-free HDL 3 or acetylated LDL did not 
significantly compete with 125I-LDL binding, up to 500/~g/ml. 125I-LDL binding was decreased by 
70% in HT29-18 cells preincubated for 24 hours in culture medium containing I00/zg/ml unlabelled 
LDL. Ligand blotting studies performed on HT29-18 homogenates u ing colloidal gold labelled LDL 
indicated the presence of one autoradiographic band corresponding to an apparent molecular weight 
of 130 kDa, which is consistent with the previously reported molecular weight of the LDL receptor in 
human fibroblasts. At 37~ 125I-LDL was actively internalized by HT29-18 cells and lysosomal 
degradation occurred as demonstrated by the inhibitory effect of chloroquine. LDL uptake and 
degradation by H'I29-18 cells also resulted in a marked decrease in endogenous sterol synthesis. 
These data demonstrate hat the HT29-18 human cancerous intestinal cells are able to specifically bind 
and internalize LDL, and that LDL processing results in down-regulation f sterol biosynthesis. Thus, 
intestinal epithelial cells possess pecific LDL receptors that can be exploited to accomplish drug 
delivery and gene transfer via the receptor-mediated ndocytosis pathway. 
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ABBREVIATIONS: HDL, HCL3, high density lipoprotein; LDL, low density lipoprotein. 
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INTRODUCTION 
Low density lipoprotein (LDL) is the main cholesterol carrier in plasma. It is 
catabolized in a variety of tissues by a process involving receptor-mediated 
endocytosis, resulting in down-regulation of endogenous cholesterol biosynthesis 
(1, 2). The role of intracellular cholesterol metabolism during cell growth and 
proliferation has been documented in normal and transformed tissues (3-5). 
Endogenous cholesterol synthesis is a prerequisite in the active renewal and 
differentiation of crypt cell progenitors in the small intestine and colon (6, 7). 
Recent advances in carcinogenesis research indicate that cell division and 
proliferation are certainly crucial events connected with the risk of cancer, such as 
familial polyposis coli polyps. This last correlation led us to study the interaction 
of LDL with HT29-18 human colonic cancer cells, since colorectal cancer is one 
of the most common types of malignant disease "~n Western population. 
In this paper, we investigated LDL processing and sterol synthesis in 
HT29-18 cells, a subclone obtained from a human colonic adenocarcinoma (8). 
The HT-29 cells can be primed for differentiation i to enterocyte-like and goblet 
cells following substitution of glucose for galactose in the culture medium (9, 10). 
Thus, HT29 cells constitute a suitable model to characterize the molecular and 
biochemical events related to intestinal cell proliferation and differentiation, and 
to test new therapeutic approaches against colonic cancers. 
Our findings demonstrate specific binding and internalization of LDL by 
HT29-18 cells. This process is down-regulated after preincubation of the human 
cancerous intestinal cells in the presence of LDL. We also provide evidence for a 
lysosomal catabolism of the protein moiety of LDL and for inhibition of sterol 
synthesis by LDL. 
MATERIALS AND METHODS 
Materials 
125INa (13-17 Ci/mg) was from Amersham (Buckinghamshire, U.K.). [2- 
14 C] sodium acetate (55 mCi/mmol) was from CEA (Saclay, France). Dulbecco's 
modified minimum essential medium (DMEM) with Earle's salts and fetal calf 
serum were from Gibco (Grand Island, N.Y., U.S.A.). Ultroser G was purchased 
from Industries Biologiques Franqaises (Villeneuve la Garenne, France). Silicagel 
plates F 1500 were from Schleicher and Schuell (Dassel, W. Germany). 
Cell Culture 
The HT29-18 subclone generously provided by Dr. D. Louvard (Unit6 de 
Biologie des Membranes, Institut Pasteur, Paris, France) was cultured in DMEM 
supplemented with 10% fetal calf serum as previously described (8). Experiments 
were performed on confluent cell monolayers, approximately 3 to 4 days after 
seeding. 
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LDL Preparation and Labelling with ~2SlNa: 
LDL was prepared from normal human serum by 3 steps ultracentrifugation 
at 105,000 • g in a L8-55 Beckman centrifuge, according to Havel et al. (11). The 
LDL was taken as the 1.024-1.050 density fractions. After dialysis against 0.1 M 
glycine/0.1MNaOH buffer (pH=10),  the LDL was iodinated using l mCi 
125INa/mg LDL, according to Bilheimer et al. (12). After labelling, the LDL was 
extensively dialyzed against 0.1 M Tris-HCl buffer (pH=7.4),  filtered through 
0.4:5/~m Millipore filters and stored at 4~ The specific radioactivity was about 
250-350 dpm/ng of LDL protein. Free 12Siodine in the preparation was under 
2%. Protein determination was done by the Lowry method (13). 
Preparation of LDL Colloidal Gold Conjugates 
Colloidal gold was prepared according to Frens (14) in order to obtain 17 nm 
gold particles. Conjugation of LDL to gold particles was performed as described 
by Handley et al. (15), and modified by Robenek et al. (16). 
LDL Binding, Uptake and Degradation 
HT29-18 cells were cultured for 24 hours in DMEM medium supplemented 
with 2% of the serum substitute Ultroser G, instead of fetal calf serum for 
maximum LDL receptor expression. Cells were then washed 3 times with 
phosphate buffered saline (PBS, pH = 7.4). Binding, uptake and degradation of 
125-I-LDL were studied according to Goldstein and Brown (1). The nonspecific 
component of 125I-LDL binding, uptake or degradation was determined by 
addition of a 50-fold excess of unlabelled LDL along with the tracer. The specific 
component was calculated from the difference between total and nonspecific 
binding, uptake or degradation. Results are expressed as ng bound LDL/mg of 
cell protein. 
Visualization of the LDL Receptor by Ligand Blotting 
The LDL receptor molecule was also identified by the ligand blotting method 
(17). About 20 • 106 cells were solubilized with 1.5% Triton X 100 according to 
Friedman et al. (18). SDS-polyacrylamide g l electrophoresis was performed on a 
homogeneous Phastgel 7.5 with a Phastsystem (Pharmacia, Upsala, Sweden), and 
proteins were transferred on a nitrocellulose sheet using a semi-dry transfer 
system (NovaBlot, Pharmacia). The nitrocellulose was then incubated for 2 h at 
room temperature with 140 ~g/ml colloidal gold-labelled LDL. The LDL/gold 
particle ratio was 7/1 as assessed by electron microscopy, thus corresponding to 
20 #g/ml of unlabelled LDL. The LDL-receptor complex was revealed using the 
IntenSE BL silver enhancement kit (Janssen Life Sciences Products, Beerse, 
Belgium). 
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Lipid Synthesis 
Cells were cultured for 24 h in DMEM supplemented with 2% Ultroser G for 
maximal induction of sterol synthesis, and then incubated for 4 h at 37~ in the 
presence of 10#Ci/ml sodium aac-acetate. After three washes with PBS, 
HT29-18 cells were harvested with a rubber policeman. Lipid analysis was 
performed by thin layer chromatography, as preveously described (19). Results 
are expressed as pmol of 14C-acetate incorporated/mg of cell protein. 
All experiments were repeated at least 3 times in duplicate. Where appropriate, 
statistical analysis was performed using the Student's t test. 
RESULTS 
Figure la shows the specific binding of ~esI-LDL in HT29-18 cells as a 
function of the lipoprotein concentration. At 4~ a plateau was observed for 
about 40/~g/ml ipoproteins. Scatchard analysis (20) indicated a Kd value of 
11/~g/ml, close to that found by Nano et al. in the rat intestinal cell line IRD98 
(7). The maximal binding capacity was about 85 ng LDL protein/mg cell protein. 
The nonspecific binding represented 23% of the total xasI-LDL binding. When 
HT28-18 cells were incubated at 4~ in the presence of 10/~g/ml ~25I-LDL, the 
plateau was reached after 1 h incubation (Fig. lb). Thus, LDL  binding in 
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Fig. 1. Specific binding of lzSI-LDL to HT29-18 human colonic cancer cells, a: ~251-LDL 
binding as a function of LDL concentration. Cells were cultured for 24 h in Dulbecco's MEM 
medium supplemented with 2% Ultroser G. Then 125I-LDL binding was measured at4~ in the 
presence of various concentrations of 125I-LDL ranging from 2.5 to 100/~g/ml. Results are 
expressed as ng of 125I-LDL bound/mg of cell protein (data are means of 4 experiments), b: 
Specific ~zSI-LDL binding to HT29-18 cells as function of time. Incubations were performed at 
4~ in the presence of 10 ~g/ml eeI-LDL. Results are expressed asng 1zsI-LDL bound per mg 
of cell protein (data are means of 3 experiments). 
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Fig. 2. Kinetics of specific 125I-LDL uptake 
(A) and degradation (0) in HT29-18 cells. 
Cells were cultured for 24 h in the presence of 
Ultroser instead of FCS, as indicated in the 
legend of Figure 1. Then, the uptake and 
degradation of LDL were studied at 37~ in the 
presence of 10#g/ml ~25I-LDL. Results are 
expressed as ng lzsI-LDL internalized or de- 
graded (data are means of 6 experiments). 
HT29-18 cells appeared to be a saturable process, in relation to time and LDL 
concentration. 
Figure 2 shows the kinetics of 125I-LDL internalization and degradation i
HT29-18 cells incubated at 37~ LDL uptake plateaued after 1 h incubation, 
while LDL degradation was negligible and increased linearly until 4 h incubation. 
The lysosomal inhibitor chloroquine reduced in a dose-dependent manner 
125I-LDL degradation by HT29-18 cells. At the concentration of 1 raM, this drug 
inhibited degradation by 80% (Figure 3). This result suggests that the protein 
moiety of LDL is degraded in lysosomes in HT29-18 cells, as previously observed 
in various cell types, including fibroblasts (21) and hepatocytes (22). 
In order to study the specificity of the 125I-LDL binding, competition 
experiments were performed with increasing concentrations of unlabelled LDL, 
apo E-free HDL3 or acetylated LDL. Figure 4 shows that 125I-LDL binding was 
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Fig. 3. Effect of chloroquine on 125I-LDL 
degradation i  HT29-18 cells. Cells were in- 
cubated for 4h at 37~ in the presence of 
10/~g/ml 125I-LDL alone or combined with the 
indicated concentrations of chloroquine. Re- 
suits are expressed as percent of control 
(100%: 235 • 34ng/mg of cell protein). Data 
are means of 4 experiments. 
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Fig. 4. Competition between unlabelled LDL (A), 
unlabelled acetylated LDL (U) or unlabelled HDL3 (0) 
with lzSI-LDL binding in HT29-18 cells. The cells were 
incubated for 1 h at 4~ in the presence of 10#g/ml 
lzSI-LDL alone or the indicated agents. Results are 
expressed as percent of control (100%: 42 + 3 ng/mg of 
cell protein). Data are means of 4 experiments. 
efficiently displaced by unlabelled LDL,  resulting in 60% and 80% inhibition of 
binding at the LDL concentrations of 25 and 250/tg/ml, respectively. In contrast, 
unlabelled HDL3 or acetylated LDL  did not significantly compete with 125I-LDL 
binding, in the range of the concentrations studied. 
Figure 5 displays the ligand-blotting identification of the LDL receptor in 
HT29-18 cells (lane c). A cell extract of MRC5 normal human fibroblasts has 
also been studied as a positive control (lane a). It can be observed that in 
non-reducing conditions, in the absence of fl-mercaptoethanol, nly one band 
was obtained, which was located at the same position in the 2 cell types, 
corresponding to an apparent molecular weight of 130 kDa. This is consistent 
with the molecular weight of the LDL receptor obtained in human fibroblasts 
treated under similar conditions (23). It can also be observed in Fig. 5 that when 
experiments were performed in the presence of an excess of native LDL (at 
500/~g/ml), no autoradiographic band was detectable in HT29-18 cells and 
fibroblasts (lanes d and b). In the presence of 1 mM EDTA,  no band was 
observed either with MRC5 fibroblasts or with HT29 extracts (data not shown), 
indicating that LDL  binding by the HT29-18 LDL  receptor is dependent upon the 
presence of free calcium, as previously observed in human fibroblasts (24). When 
incubated in reducing conditions, in the presence of /3-mercaptoethanol, the 
apparent molecular weight of the LDL receptor in HT29-18 cells shifted to 
160 kDa (data not shown). Similar findings have been reported for the apo B /E  
receptor in human fibroblasts (23). Our data indicate that the LDL receptor in 
ITI~9-18 human colonic carcinoma cells has the same molecular weight and 
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Fig. 5. Ligand blots of the LDL receptor in MRC5 human 
fibroblasts (a, b) and HT29-18 human colonic carcinoma cells 
(c, d). Samples obtained from Triton • extracts were 
subjected to SDS-PAGE in a 7.5% homogeneous Phastgel 
and transferred electrophoretically to nitrocellulose paper. 
The blots were incubated with LDL-gold conjugates 
(140 #g/ml) in the absence (a, c) or in the presence (b, d) of 
an excess of unlabeled LDL (500#g/ml). Migrations f 
molecular weight standards transferred onto the nitrocellulose 
paper are illustrated on the left. 
calcium dependency than the apo B /E  receptor in human fibroblasts. 
The down-regulation of the LDL  receptor by exogenous LDL  was also 
investigated in HT29-18 cells incubated for 24 h in culture medium supplemented 
with increasing concentrations of unlabelled LDL. The LDL  treatment resulted in 
a dose-dependent decrease of 125I-LDL binding (Figure 6). Half-maximal and 
maximal down-regulation were respectively observed at the concentrations of 
unlabelled LDL  of 25 and 250/~g/ml. The effect of unlabelled LDL  incubated for 
24 h on lipid synthesis in HT29-18 cells is presented in Table 1. It can be observed 
that LDL induced a dose-dependent decrease in sodium 14C-acetate incorporation 
into sterols (38% and 66% decrease for LDL  at 10 and 50/~g/ml, respectively). 
In contrast, incorporation of the precursor into triacylglycerols or total phos- 
pholipids was much less affected. 
DISCUSSION 
There are only few data concerning the LDL  processing by intestinal 
epiithelial cells. In rats, specific LDL  binding has been described by Suzuki et al. 
in enzyme-dispersed mucosal cells (25), and more recently by Nano et al. in the 
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Fig. 6. Down-regulation by LDL of specific 12sI- 
LDL binding in human colonic cancer cells HT29- 
18. After 24 h culture in DMEM supplemented with 
2% Ultroser G and the indicated concentrations of 
LDL, HT29-18 cells were washed 3 times with PBS 
and incubated for 1 h at 4~ in the presence of 
10 ttg/ml 125I-LDL. Results are expressed as percent 
of control (100%: 40:t:7ng/mg of cell protein). 
Data are means of 3 experiments. 
epithelial cell line IRD 98 established from explants of fetal small intestine (7). In 
the present work, we clearly demonstrate that the human cancerous colonic 
HT29-18 cells can bind, internalize and degrade LDL in a specific manner. The 
specificity of the LDL receptor in HT29-18 cells is illustrated by the absence of 
competition between the 125I-LDL binding sites and apo E-free HDL3 or  
acetylated LDL. Internalization and lysosomal degradation occurs, as dem- 
Table 1. Effect of LDL on lipid synthesis from sodium 14C-acetate 
in HT29-18 cells 
Addition laC-acetate incorporation i to: 
Sterols Triacylglycerols Phospholipids 
None 1193 • 145 1801 + 252 3872 -1- 508 
LDL, 
10/tg/ml 698 5- 89*** 1514 + 195 3340 + 455 
25/~g/ml 455 i 67*** 1295 + 144" 2989 + 308 
50/~g/ml 412 :k 55*** 1187 + 156" 2626 + 325 
Cell monolayers were preincubated for 24h in the absence or 
presence of 10 to 50 #~ LDL/ml in DMEM supplemented with 2% 
Ultroser G. Sodium 1 C-acetate (10/tCi/ml) was added for 4 h at 
37~ Lipid analysis was performed by thin layer chromatography. 
Results are means of 6 experiments+s.d. *: p <0.05; ***: p< 
0.001 by the Student's t test. 
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onstrated by the decrease in lzSI-labelled peptides released in the incubation 
medium and the intracellular accumulation of 125I-LDL in the presence of 
chloroquine. Moreover, post-receptor events took place, as demonstrated by the 
down-regulation of 125I-LDL binding and of sterol biosynthesis n HT29-18 cells 
cultured in the presence of LDL. Finally, the existence of the receptor for LDL in 
HT29-18 cells is directly demonstrated by ligand blotting studies. 
At the present ime, the pathophysiological significance of LDL processing in 
carcinoma-derived colonic epithelial cells, and its occurrence in normal human 
intestine remained undefined. Although the subclone xamined in this study was 
obtained from a primary colonic carcinoma, there is evidence that cells of the 
H'1-29 line resemble normal human intestinal epithelial cells with respect to 
several morphologic, biochemical, functional and immunological criteria. These 
include villin and intestinal brush border enzyme synthesis, expression of 
vasoactive intestinal peptide receptors, EGF and oL2-adrenergic receptors, and 
preservation of mucin-associated antigens (9, 10, 26, 27). Undifferentiated HT29 
cells proliferate as unpolarized layers in a standard culture medium and undergo 
enterocyte or goblet cell differentiation after glucose privation or butyrate 
treatment (29-30). This cell line therefore constitute a powerful model in the 
study of LDL and cholesterol metabolism during the maturation and the 
functional differentiation of human epithelial cells. The developmental pattern of 
the LDL pathway in normal intestinal epithelial cells remains to be explored in 
view of the dietary changes occurring in the suckling newborn and at the weaning 
(30). It is therefore tempting to suggest that milk lipoproteins and dietary 
proteins can exert a physiological regulation on the processing of LDL in 
intestine. 
HT29-18 cells also appear to be an interesting model to study the targeting 
and transfer of genes and some therapeutic agents via the LDL receptor pathway. 
Several epidemiological nd laboratory animal model studies indicate that the 
aetiology of colon cancer is multifactorial and complex (27). Surgical excision has 
be.en considered as the only effective treatment for colon cancer. However, the 
prognosis of patients with colorectal cancer remains poor, mainly due to the 
occurrence of metastatic invasions and resistance to chemotherapy involving 
maltiresistance gene expression and other mechanisms (31-36). Gene-based 
therapy via the LDL receptor-mediated pathway, using LDL covalently linked to 
DNA-binding structures uch as polyamines, polylysines or other conjugates will 
allow the delivery of genetic informations encoding anti-metastatic, anti- 
o~cogenic functions, such as tumor suppressor proteins or antisens elements. 
Some studies are also concerned with the role of LDL in the transport of 
hydrophobic anticancer drugs, especially anticancer porphyrin derivatives (37- 
41). LDL has been shown to be the most potent vehicle for delivering anticancer 
porphyrins to cells. Tumors which can be reached by external or endoscopic 
irradiation, and among them colorectal cancers, are good targets for photo- 
dynamic therapy. Studies are now in progress to investigate the different 
mechanisms involved in the lytic processes related to the delivery of porphyrins to 
ITF29-18 cells through the LDL pathway. 
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